Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

DBC1 (Deleted in Breast Cancer 1) modulates the stability and function of the nuclear receptor Rev-erbα
Chini, Claudia C.S. , Escande, Carlos , Nin, Verónica , Chini, Eduardo N.

Biochemical Journal | February 13, 2013 | Volume: 451 | Issue: 3 | Pages: 453-461

10.1042/bj20121085 | PMID 23398316 Get It

The nuclear receptor Rev-erbα has been implicated as a major regulator of the circadian clock and integrates circadian rhythm and metabolism. Rev-erbα controls circadian oscillations of several clock genes and Rev-erbα protein degradation is important for maintenance of the circadian oscillations and also for adipocyte differentiation. Elucidating the mechanisms that regulate Rev-erbα stability is essential for our understanding of these processes. In the present paper, we report that the protein DBC1 (Deleted in Breast Cancer 1) is a novel regulator of Rev-erbα. Rev-erbα and DBC1 interact in cells and in vivo, and DBC1 modulates the Rev-erbα repressor function. Depletion of DBC1 by siRNA (small interfering RNA) in cells or in DBC1-KO (knockout) mice produced a marked decrease in Rev-erbα protein levels, but not in mRNA levels. In contrast, DBC1 overexpression significantly enhanced Rev-erbα protein stability by preventing its ubiquitination and degradation. The regulation of Rev-erbα protein levels and function by DBC1 depends on both the N-terminal and C-terminal domains of DBC1. More importantly, in cells depleted of DBC1, there was a dramatic decrease in circadian oscillations of both Rev-erbα and BMAL1. In summary, our data identify DBC1 as an important regulator of the circadian receptor Rev-erbα and proposes that Rev-erbα could be involved in mediating some of the physiological effects of DBC1.
Outcome and Toxicity for Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer
Vora, Sujay A., Wong, William W. , Schild, Steven E. , Ezzell, Gary A., Ferrigni, Robert G., Swanson, Scott K., Andrews, Paul , Schild, Steven

Journal of Urology | February 13, 2013 | Volume: 190 | Issue: 2 | Pages: 521-526

10.1016/j.juro.2013.02.012 | PMID 23415964 Get It

Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis
Winnick, Jason J. , Ramnanan, Christopher J. , Saraswathi, Viswanathan , Roop, Joshua, Jacobson, Peer B., Jung, Paul , Basu, Rita , Cherrington, Alan D. , Scott, M. , Edgerton, Dale S.

American Journal of Physiology-Endocrinology and Metabolism | February 13, 2013 | Volume: 304 | Issue: 7 | Pages: E747-E756

10.1152/ajpendo.00639.2012 | PMID 23403942 Get It

The aim of this study was to determine the effect of prolonged 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibition on basal and hormone-stimulated glucose metabolism in fasted conscious dogs. For 7 days prior to study, either an 11β-HSD1 inhibitor (HSD1-I; n = 6) or placebo (PBO; n = 6) was administered. After the basal period, a 4-h metabolic challenge followed, where glucagon (3×-basal), epinephrine (5×-basal), and insulin (2×-basal) concentrations were increased. Hepatic glucose fluxes did not differ between groups during the basal period. In response to the metabolic challenge, hepatic glucose production was stimulated in PBO, resulting in hyperglycemia such that exogenous glucose was required in HSD-I ( P < 0.05) to match the glycemia between groups. Net hepatic glucose output and endogenous glucose production were decreased by 11β-HSD1 inhibition ( P < 0.05) due to a reduction in net hepatic glycogenolysis ( P < 0.05), with no effect on gluconeogenic flux compared with PBO. In addition, glucose utilization ( P < 0.05) and the suppression of lipolysis were increased ( P < 0.05) in HSD-I compared with PBO. These data suggest that inhibition of 11β-HSD1 may be of therapeutic value in the treatment of diseases characterized by insulin resistance and excessive hepatic glucose production.
Faculty Opinions recommendation of The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis.
Fernández-Zapico, Martín E.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 13, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717977054.793470659 Get It

Hyperammonemic Coma in an Adult due to Ornithine Transcarbamylase Deficiency
Roberts, Daniel L. , Galbreath, David A., Patel, B. M. , Ingall, Timothy J., Khatib, Amer , Johnson, Daniel J.

Case Reports in Critical Care | February 12, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/493216 | PMID 24804122 Get It

Objective. To report an unusual cause of coma in an adult.Design. Case report.Setting. University teaching hospital.Patient. A previously healthy 53-year-old man initially presented with altered mental status and progressed to coma. He was found to be substantially hyperammonemic and did not improve with lactulose therapy and continuous venovenous hemodialysis.Results. Biochemical testing revealed previously undiagnosed ornithine transcarbamylase deficiency, and the patient responded to arginine, sodium phenylacetate, and sodium benzoate.Conclusion. Even in adult patients with no known history, inborn errors of metabolism must be considered in the differential diagnosis of unexplained coma. Defects of the urea cycle can present with an unprovoked hyperammonemic coma.
Acute Systemic Viral Infection Masquerading as an Infiltrating Lymphoma in an Elderly Patient: A Case Report and Review of the Literature
Babiker, Hani M. , Wiedenbeck, Troy, Robetorye, Ryan S. , Acharya, Utkarsh , Wilansky, Susan , Kusne, Shimon , Wiedenbeck, Troy L. , Babiker, Hani

Case Reports in Medicine | February 12, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-5

10.1155/2013/318358 | PMID 23476662 Get It

Primary Epstein-Barr virus (EBV) infection occurs mainly in adolescents and young adults, with more than 90% of adults having serological evidence of past infection. Primary infection in those over the age of 40 is associated with an atypical and often more severe presentation that can lead to more extensive and invasive, and often unnecessary, diagnostic testing. The incidence of severe EBV-related illness in older adults has been observed to be increasing in industrialized nations. The characteristic presentation of infectious mononucleosis (IM) syndrome in elderly patients (age > 65) is not clearly defined in the literature. Here, we describe a case of primary EBV infection in an 80-year-old female and review the literature regarding primary seroconversion in elderly patients.
After a doomed patient kills himself: a psychiatrist's reflections
Bostwick, John

Bipolar Disorders | February 12, 2013 | Volume: 15 | Issue: 5 | Pages: 628-631

10.1111/bdi.12051 | PMID 23398471 Get It

Faculty Opinions recommendation of Objective outcomes 14 years after laparoscopic anterior 180-degree partial versus nissen fundoplication: results from a randomized trial.
Iyer, Prasad G. , Singh, Siddharth

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 12, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717969251.793470524 Get It

Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
Kourelis, Taxiarchis , Lacy, Martha Q. , Kyle, Robert A. , Kapoor, Prashant , Zeldenrust, Steven R., Hayman, Suzanne R. , Lust, John A., Russell, Stephen J. , Lin, Yi , Rajkumar, S. Vincent , Kumar, Shaji , Leung, Nelson , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Zent, Clive S. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

American Journal of Hematology | February 12, 2013 | Volume: 88 | Issue: 5 | Pages: 375-378

10.1002/ajh.23413 | PMID 23508840 Get It

To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non‐AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non‐AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non‐AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non‐AL is nearly as common. Distinguishing between these two groups is essential since patients with non‐AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis. Am. J. Hematol. 88:375–378, 2013. © 2013 Wiley Periodicals, Inc.